Tonix soars as CEO presents at conference

|About: Tonix Pharmaceuticals Ho... (TNXP)|By:, SA News Editor

CEO Seth Lederman makes the case for Tonix Pharmaceuticals (TNXP +29.1%) at the LD Micro VI conference in Los Angeles, though his presentation doesn't appear to contain any new information.

Webcast and presentation slides

Results from the pivotal Phase 2b/3 trial of TNX-102 SL for fibromyalgia are expected in 2014 H2, and the Phase 2a trial of the drug for treating PTSD is expected to begin in 2014 Q2.

Earlier this week: SA Pro's Joe Springer on the opportunity in Tonix.